Co-Authors
This is a "connection" page, showing publications co-authored by Karolina Akinosoglou and Evangelos Giamarellos-Bourboulis.
Connection Strength
1.751
-
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021 10; 27(10):1752-1760.
Score: 0.241
-
An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife. 2021 03 08; 10.
Score: 0.233
-
Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus. Shock. 2020 11; 54(5):633-637.
Score: 0.228
-
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care. 2020 04 30; 24(1):187.
Score: 0.220
-
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020 06 10; 27(6):992-1000.e3.
Score: 0.220
-
Progression into sepsis: an individualized process varying by the interaction of comorbidities with the underlying infection. BMC Infect Dis. 2018 05 29; 18(1):242.
Score: 0.192
-
How well does qSOFA correspond to underlying systemic inflammatory response? Cytokine. 2018 10; 110:288-290.
Score: 0.188
-
Platelet reactivity in sepsis syndrome: results from the PRESS study. Eur J Clin Microbiol Infect Dis. 2017 Dec; 36(12):2503-2512.
Score: 0.183
-
Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. 2017 09 18; 15(1):172.
Score: 0.046